Abstract
Alglucosidase alfa is a recombinant form of acid α-glucosidase that catalyses the complete hydrolysis of its natural substrate, glycogen. It is postulated that administration of alglucosidase alfa will result in clearance of glycogen from lysosomes and will improve muscle function in patients affected with Pompe disease. This review describes the main steps in the history of enzyme-replacement therapy in this specific lysosomal storage disorder and discusses the characteristics of the medicinal product as well as the evaluation of response to therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
